eDrugSearch uploadxml
eDrug Search

View drugs by alphabetical list:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

  • Home
  • Pharmacy Ratings
  • Blog
  • Community
  • Library
  • About Pharmacies
  • Tell a Friend:

You are here:Home»Prescription Drugs A to Z»Invega

Invega Price Comparison

Buy Invega Online and Read Invega Reviews

Use eDrugSearch to check Invega price comparison results below and read verified Invega reviews before you buy Invega online. Simply click the "Buy Now" button or the "Pharmacy Logo" to buy Invega online from one of our licensed Canadian pharmacies.

*To refine your Invega price comparison search further click on the "All, Brand or Generic" tab so you can view all the Invega prices located within our database.

Select Dosage

  • All dosages
  • 3mg Invega
  • 6mg Invega
  • 9mg Invega
  • 50 mg Invega
  • 75 mg Invega
  • 100 mg Invega
  • 150 mg Invega
  • Compare Prices
  • Read Reviews
  • Q & A
  • Description
  • Coupons
  • All
  • Brand
  • Generic
Online Pharmacydesc
Drug Namedesc
Quantitydesc
Total Pricedesc
Price Per Pilldesc
Check Availability

Invega Prices from Online Canadian Pharmacy

Invega 3mg

30
Brand

$142.19

viewdetail

$ 4.74

Go To STORE
53.83%
When you buy 1 container of Invega 3mg for $142.19 at Online Canadian Pharmacy compared to the max price for 30 of $308.00.
1 container (30): Invega 3mg
$142.19
Regular Shipping:
$0.00
Total:
$142.19
Go To Store

Invega Prices from BuyLow Drugs

Invega 3mg

30
Brand

$155.00

viewdetail

$ 5.17

Go To STORE
49.68%
When you buy 1 container of Invega 3mg for $155.00 at BuyLow Drugs compared to the max price for 30 of $308.00.
1 container (30): Invega 3mg
$155.00
Regular Shipping:
$0.00
Total:
$155
Go To Store

Invega Prices from CanadianPharmacyKing

Invega 6 mg

28
Brand

$179.00

viewdetail

$ 6.39

Go To STORE
57.18%
When you buy 1 container of Invega 6 mg for $179.00 at CanadianPharmacyKing compared to the max price for 28 of $418.00.
CanadianPharmacyKing Pharmacy is certified by
1 container (28): Invega 6 mg
$179.00
Regular Shipping:
$10.00
Total:
$189
Go To Store

Invega Prices from Canada Drug Center

Invega 3mg

84
Brand

$549.00

viewdetail

$ 6.54

Go To STORE
19.50%
When you buy 1 container of Invega 3mg for $549.00 at Canada Drug Center compared to the max price for 84 of $682.00.
Canada Drug Center Pharmacy is certified by
1 container (84): Invega 3mg
$549.00
Regular Shipping:
$9.99
Coupon Discount
$55.899
Total:
$503.091
Go To Store

Invega Prices from Canadian Pharmacy Meds

Invega 3mg

84
Brand

$550.00

viewdetail

$ 6.55

Go To STORE
19.35%
When you buy 1 container of Invega 3mg for $550.00 at Canadian Pharmacy Meds compared to the max price for 84 of $682.00.
Canadian Pharmacy Meds Pharmacy is certified by
1 container (84): Invega 3mg
$550.00
Regular Shipping:
$10.00
Coupon Discount
$56
Total:
$504
Go To Store

Invega Prices from Online Pharmacies Canada

Invega 3mg

30
Brand

$196.63

viewdetail

$ 6.55

Go To STORE
36.16%
When you buy 1 container of Invega 3mg for $196.63 at Online Pharmacies Canada compared to the max price for 30 of $308.00.
Online Pharmacies Canada Pharmacy is certified by
1 container (30): Invega 3mg
$196.63
Regular Shipping:
$9.95
Total:
$206.58
Go To Store

Invega Prices from Quality Prescription Drugs

Invega 3mg

30
Brand

$197.13

viewdetail

$ 6.57

Go To STORE
36.00%
When you buy 1 container of Invega 3mg for $197.13 at Quality Prescription Drugs compared to the max price for 30 of $308.00.
Quality Prescription Drugs Pharmacy is certified by
1 container (30): Invega 3mg
$197.13
Regular Shipping:
$9.00
Total:
$206.13
Go To Store

Invega Prices from Pharma Passport

Invega 3mg

30
Brand

$197.62

viewdetail

$ 6.59

Go To STORE
35.84%
When you buy 1 container of Invega 3mg for $197.62 at Pharma Passport compared to the max price for 30 of $308.00.
1 container (30): Invega 3mg
$197.62
Regular Shipping:
$9.95
Total:
$207.57
Go To Store

Invega Prices from Canadian Pharmacy Meds

Invega 6mg

84
Brand

$555.00

viewdetail

$ 6.61

Go To STORE
18.62%
When you buy 1 container of Invega 6mg for $555.00 at Canadian Pharmacy Meds compared to the max price for 84 of $682.00.
Canadian Pharmacy Meds Pharmacy is certified by
1 container (84): Invega 6mg
$555.00
Regular Shipping:
$10.00
Coupon Discount
$56.5
Total:
$508.5
Go To Store

Invega Prices from Canada Drug Center

Invega 3mg

56
Brand

$375.00

viewdetail

$ 6.70

Go To STORE
20.55%
When you buy 1 container of Invega 3mg for $375.00 at Canada Drug Center compared to the max price for 56 of $472.00.
Canada Drug Center Pharmacy is certified by
1 container (56): Invega 3mg
$375.00
Regular Shipping:
$9.99
Coupon Discount
$38.499
Total:
$346.491
Go To Store

Invega Prices from Canadian Pharmacy Meds

Invega 3mg

56
Brand

$376.00

viewdetail

$ 6.71

Go To STORE
20.34%
When you buy 1 container of Invega 3mg for $376.00 at Canadian Pharmacy Meds compared to the max price for 56 of $472.00.
Canadian Pharmacy Meds Pharmacy is certified by
1 container (56): Invega 3mg
$376.00
Regular Shipping:
$10.00
Coupon Discount
$38.6
Total:
$347.4
Go To Store

Invega Prices from Canadian Pharmacy Meds

Invega 6mg

56
Brand

$381.00

viewdetail

$ 6.80

Go To STORE
19.28%
When you buy 1 container of Invega 6mg for $381.00 at Canadian Pharmacy Meds compared to the max price for 56 of $472.00.
Canadian Pharmacy Meds Pharmacy is certified by
1 container (56): Invega 6mg
$381.00
Regular Shipping:
$10.00
Coupon Discount
$39.1
Total:
$351.9
Go To Store

Invega Prices from Canada Drug Center

Invega 3mg

28
Brand

$195.00

viewdetail

$ 6.96

Go To STORE
53.35%
When you buy 1 container of Invega 3mg for $195.00 at Canada Drug Center compared to the max price for 28 of $418.00.
Canada Drug Center Pharmacy is certified by
1 container (28): Invega 3mg
$195.00
Regular Shipping:
$9.99
Coupon Discount
$20.499
Total:
$184.491
Go To Store

Invega Prices from Canadian Pharmacy Meds

Invega 3mg

28
Brand

$196.00

viewdetail

$ 7.00

Go To STORE
53.11%
When you buy 1 container of Invega 3mg for $196.00 at Canadian Pharmacy Meds compared to the max price for 28 of $418.00.
Canadian Pharmacy Meds Pharmacy is certified by
1 container (28): Invega 3mg
$196.00
Regular Shipping:
$10.00
Coupon Discount
$20.6
Total:
$185.4
Go To Store

Invega Prices from CanadianPharmacyKing

Invega 9 mg

28
Brand

$199.00

viewdetail

$ 7.11

Go To STORE
52.39%
When you buy 1 container of Invega 9 mg for $199.00 at CanadianPharmacyKing compared to the max price for 28 of $418.00.
CanadianPharmacyKing Pharmacy is certified by
1 container (28): Invega 9 mg
$199.00
Regular Shipping:
$10.00
Total:
$209
Go To Store

Invega Prices from Canadian Pharmacy Meds

Invega 6mg

28
Brand

$202.00

viewdetail

$ 7.21

Go To STORE
51.67%
When you buy 1 container of Invega 6mg for $202.00 at Canadian Pharmacy Meds compared to the max price for 28 of $418.00.
Canadian Pharmacy Meds Pharmacy is certified by
1 container (28): Invega 6mg
$202.00
Regular Shipping:
$10.00
Coupon Discount
$21.2
Total:
$190.8
Go To Store

Invega Prices from JanDrugs

Invega ER 3mg

90 tablet
Brand

$673.80

viewdetail

$ 7.49

Go To STORE
19.50%
When you buy 1 container of Invega ER 3mg for $673.80 at JanDrugs compared to the max price for 90 tablet of $837.00.
JanDrugs Pharmacy is certified by
1 container (90 tablet): Invega ER 3mg
$673.80
Regular Shipping:
$0.00
Coupon Discount
$67.38
Total:
$606.42
Go To Store

Invega Prices from Canada Drugs

Invega ER 3mg

90 tablet
Brand

$673.80

viewdetail

$ 7.49

Go To STORE
19.50%
When you buy 1 container of Invega ER 3mg for $673.80 at Canada Drugs compared to the max price for 90 tablet of $837.00.
Canada Drugs Pharmacy is certified by
1 container (90 tablet): Invega ER 3mg
$673.80
Regular Shipping:
$0.00
Coupon Discount
$168.45
Total:
$505.35
Go To Store

Invega Prices from BuyLow Drugs

Invega 6mg

30
Brand

$227.00

viewdetail

$ 7.57

Go To STORE
26.30%
When you buy 1 container of Invega 6mg for $227.00 at BuyLow Drugs compared to the max price for 30 of $308.00.
1 container (30): Invega 6mg
$227.00
Regular Shipping:
$0.00
Total:
$227
Go To Store

Invega Prices from JanDrugs

Invega ER 6mg

84 tablet
Brand

$645.12

viewdetail

$ 7.68

Go To STORE
5.41%
When you buy 1 container of Invega ER 6mg for $645.12 at JanDrugs compared to the max price for 84 tablet of $682.00.
JanDrugs Pharmacy is certified by
1 container (84 tablet): Invega ER 6mg
$645.12
Regular Shipping:
$0.00
Coupon Discount
$64.512
Total:
$580.608
Go To Store

Invega Prices from Canada Drugs

Invega ER 6mg

84 tablet
Brand

$645.12

viewdetail

$ 7.68

Go To STORE
5.41%
When you buy 1 container of Invega ER 6mg for $645.12 at Canada Drugs compared to the max price for 84 tablet of $682.00.
Canada Drugs Pharmacy is certified by
1 container (84 tablet): Invega ER 6mg
$645.12
Regular Shipping:
$0.00
Coupon Discount
$161.28
Total:
$483.84
Go To Store

Invega Prices from Canadian Pharmacy Meds

Invega 9mg

84
Brand

$682.00

viewdetail

$ 8.12

Go To STORE
0.00%
When you buy 1 container of Invega 9mg for $682.00 at Canadian Pharmacy Meds compared to the max price for 84 of $682.00.
Canadian Pharmacy Meds Pharmacy is certified by
1 container (84): Invega 9mg
$682.00
Regular Shipping:
$10.00
Coupon Discount
$69.2
Total:
$622.8
Go To Store

Invega Prices from JanDrugs

Invega ER 3mg

30 tablet
Brand

$244.60

viewdetail

$ 8.15

Go To STORE
20.58%
When you buy 1 container of Invega ER 3mg for $244.60 at JanDrugs compared to the max price for 30 tablet of $308.00.
JanDrugs Pharmacy is certified by
1 container (30 tablet): Invega ER 3mg
$244.60
Regular Shipping:
$0.00
Coupon Discount
$24.46
Total:
$220.14
Go To Store

Invega Prices from Canada Drugs

Invega ER 3mg

30 tablet
Brand

$244.60

viewdetail

$ 8.15

Go To STORE
20.58%
When you buy 1 container of Invega ER 3mg for $244.60 at Canada Drugs compared to the max price for 30 tablet of $308.00.
Canada Drugs Pharmacy is certified by
1 container (30 tablet): Invega ER 3mg
$244.60
Regular Shipping:
$0.00
Coupon Discount
$61.15
Total:
$183.45
Go To Store

Invega Prices from Online Pharmacies Canada

Invega 6mg

28
Brand

$229.00

viewdetail

$ 8.18

Go To STORE
45.22%
When you buy 1 container of Invega 6mg for $229.00 at Online Pharmacies Canada compared to the max price for 28 of $418.00.
Online Pharmacies Canada Pharmacy is certified by
1 container (28): Invega 6mg
$229.00
Regular Shipping:
$9.95
Total:
$238.95
Go To Store

Invega Prices from Quality Prescription Drugs

Invega 6mg

28
Brand

$229.57

viewdetail

$ 8.20

Go To STORE
45.08%
When you buy 1 container of Invega 6mg for $229.57 at Quality Prescription Drugs compared to the max price for 28 of $418.00.
Quality Prescription Drugs Pharmacy is certified by
1 container (28): Invega 6mg
$229.57
Regular Shipping:
$9.00
Total:
$238.57
Go To Store

Invega Prices from Pharma Passport

Invega 6mg

28
Brand

$230.14

viewdetail

$ 8.22

Go To STORE
44.94%
When you buy 1 container of Invega 6mg for $230.14 at Pharma Passport compared to the max price for 28 of $418.00.
1 container (28): Invega 6mg
$230.14
Regular Shipping:
$9.95
Total:
$240.09
Go To Store

Invega Prices from JanDrugs

Invega ER 6mg

28 tablet
Brand

$235.04

viewdetail

$ 8.39

Go To STORE
43.77%
When you buy 1 container of Invega ER 6mg for $235.04 at JanDrugs compared to the max price for 28 tablet of $418.00.
JanDrugs Pharmacy is certified by
1 container (28 tablet): Invega ER 6mg
$235.04
Regular Shipping:
$0.00
Coupon Discount
$23.504
Total:
$211.536
Go To Store

Invega Prices from Canada Drugs

Invega ER 6mg

28 tablet
Brand

$235.04

viewdetail

$ 8.39

Go To STORE
43.77%
When you buy 1 container of Invega ER 6mg for $235.04 at Canada Drugs compared to the max price for 28 tablet of $418.00.
Canada Drugs Pharmacy is certified by
1 container (28 tablet): Invega ER 6mg
$235.04
Regular Shipping:
$0.00
Coupon Discount
$58.76
Total:
$176.28
Go To Store

Invega Prices from Canadian Pharmacy Meds

Invega 9mg

56
Brand

$472.00

viewdetail

$ 8.43

Go To STORE
0.00%
When you buy 1 container of Invega 9mg for $472.00 at Canadian Pharmacy Meds compared to the max price for 56 of $472.00.
Canadian Pharmacy Meds Pharmacy is certified by
1 container (56): Invega 9mg
$472.00
Regular Shipping:
$10.00
Coupon Discount
$48.2
Total:
$433.8
Go To Store

Invega Prices from Canadian Pharmacy Meds

Invega 9mg

28
Brand

$243.00

viewdetail

$ 8.68

Go To STORE
41.87%
When you buy 1 container of Invega 9mg for $243.00 at Canadian Pharmacy Meds compared to the max price for 28 of $418.00.
Canadian Pharmacy Meds Pharmacy is certified by
1 container (28): Invega 9mg
$243.00
Regular Shipping:
$10.00
Coupon Discount
$25.3
Total:
$227.7
Go To Store

Invega Prices from Quality Prescription Drugs

Invega 9mg

28
Brand

$243.76

viewdetail

$ 8.71

Go To STORE
41.68%
When you buy 1 container of Invega 9mg for $243.76 at Quality Prescription Drugs compared to the max price for 28 of $418.00.
Quality Prescription Drugs Pharmacy is certified by
1 container (28): Invega 9mg
$243.76
Regular Shipping:
$9.00
Total:
$252.76
Go To Store

Invega Prices from Online Pharmacies Canada

Invega 9mg

28
Brand

$244.97

viewdetail

$ 8.75

Go To STORE
41.39%
When you buy 1 container of Invega 9mg for $244.97 at Online Pharmacies Canada compared to the max price for 28 of $418.00.
Online Pharmacies Canada Pharmacy is certified by
1 container (28): Invega 9mg
$244.97
Regular Shipping:
$9.95
Total:
$254.92
Go To Store

Invega Prices from Pharma Passport

Invega 9mg

28
Brand

$246.19

viewdetail

$ 8.79

Go To STORE
41.10%
When you buy 1 container of Invega 9mg for $246.19 at Pharma Passport compared to the max price for 28 of $418.00.
1 container (28): Invega 9mg
$246.19
Regular Shipping:
$9.95
Total:
$256.14
Go To Store

Invega Prices from CanadianPharmacyKing

Invega 3 mg

30
Brand

$278.00

viewdetail

$ 9.27

Go To STORE
9.74%
When you buy 1 container of Invega 3 mg for $278.00 at CanadianPharmacyKing compared to the max price for 30 of $308.00.
CanadianPharmacyKing Pharmacy is certified by
1 container (30): Invega 3 mg
$278.00
Regular Shipping:
$10.00
Total:
$288
Go To Store

Invega Prices from JanDrugs

Invega ER 9mg

90 tablet
Brand

$837.00

viewdetail

$ 9.30

Go To STORE
0.00%
When you buy 1 container of Invega ER 9mg for $837.00 at JanDrugs compared to the max price for 90 tablet of $837.00.
JanDrugs Pharmacy is certified by
1 container (90 tablet): Invega ER 9mg
$837.00
Regular Shipping:
$0.00
Coupon Discount
$83.7
Total:
$753.3
Go To Store

Invega Prices from Canada Drugs

Invega ER 9mg

90 tablet
Brand

$837.00

viewdetail

$ 9.30

Go To STORE
0.00%
When you buy 1 container of Invega ER 9mg for $837.00 at Canada Drugs compared to the max price for 90 tablet of $837.00.
Canada Drugs Pharmacy is certified by
1 container (90 tablet): Invega ER 9mg
$837.00
Regular Shipping:
$0.00
Coupon Discount
$209.25
Total:
$627.75
Go To Store

Invega Prices from JanDrugs

Invega ER 9mg

30 tablet
Brand

$299.00

viewdetail

$ 9.97

Go To STORE
2.92%
When you buy 1 container of Invega ER 9mg for $299.00 at JanDrugs compared to the max price for 30 tablet of $308.00.
JanDrugs Pharmacy is certified by
1 container (30 tablet): Invega ER 9mg
$299.00
Regular Shipping:
$0.00
Coupon Discount
$29.9
Total:
$269.1
Go To Store

Invega Prices from BuyLow Drugs

Invega 9mg

30
Brand

$299.00

viewdetail

$ 9.97

Go To STORE
2.92%
When you buy 1 container of Invega 9mg for $299.00 at BuyLow Drugs compared to the max price for 30 of $308.00.
1 container (30): Invega 9mg
$299.00
Regular Shipping:
$0.00
Total:
$299
Go To Store

Invega Prices from Canada Drugs

Invega ER 9mg

30 tablet
Brand

$299.00

viewdetail

$ 9.97

Go To STORE
2.92%
When you buy 1 container of Invega ER 9mg for $299.00 at Canada Drugs compared to the max price for 30 tablet of $308.00.
Canada Drugs Pharmacy is certified by
1 container (30 tablet): Invega ER 9mg
$299.00
Regular Shipping:
$0.00
Coupon Discount
$74.75
Total:
$224.25
Go To Store

Invega Prices from DoctorSolve

Invega 3mg

30
Brand

$308.00

viewdetail

$ 10.27

Go To STORE
0.00%
When you buy 1 container of Invega 3mg for $308.00 at DoctorSolve compared to the max price for 30 of $308.00.
DoctorSolve Pharmacy is certified by
1 container (30): Invega 3mg
$308.00
Regular Shipping:
$9.95
Coupon Discount
$79.4875
Total:
$238.4625
Go To Store

Invega Prices from MapleLeafMeds

Invega 3mg

30
Brand

$308.00

viewdetail

$ 10.27

Go To STORE
0.00%
When you buy 1 container of Invega 3mg for $308.00 at MapleLeafMeds compared to the max price for 30 of $308.00.
MapleLeafMeds Pharmacy is certified by
1 container (30): Invega 3mg
$308.00
Regular Shipping:
$9.95
Total:
$317.95
Go To Store

Invega Prices from PrescriptionPoint

Invega 3mg

30
Brand

$308.00

viewdetail

$ 10.27

Go To STORE
0.00%
When you buy 1 container of Invega 3mg for $308.00 at PrescriptionPoint compared to the max price for 30 of $308.00.
PrescriptionPoint Pharmacy is certified by
1 container (30): Invega 3mg
$308.00
Regular Shipping:
$9.95
Total:
$317.95
Go To Store

Invega Prices from Online Canadian Pharmacy

Invega 6mg

28
Brand

$314.83

viewdetail

$ 11.24

Go To STORE
24.68%
When you buy 1 container of Invega 6mg for $314.83 at Online Canadian Pharmacy compared to the max price for 28 of $418.00.
1 container (28): Invega 6mg
$314.83
Regular Shipping:
$0.00
Total:
$314.83
Go To Store

Invega Prices from DoctorSolve

Invega 6mg

28
Brand

$318.00

viewdetail

$ 11.36

Go To STORE
23.92%
When you buy 1 container of Invega 6mg for $318.00 at DoctorSolve compared to the max price for 28 of $418.00.
DoctorSolve Pharmacy is certified by
1 container (28): Invega 6mg
$318.00
Regular Shipping:
$9.95
Coupon Discount
$81.9875
Total:
$245.9625
Go To Store

Invega Prices from MapleLeafMeds

Invega 6mg

28
Brand

$318.00

viewdetail

$ 11.36

Go To STORE
23.92%
When you buy 1 container of Invega 6mg for $318.00 at MapleLeafMeds compared to the max price for 28 of $418.00.
MapleLeafMeds Pharmacy is certified by
1 container (28): Invega 6mg
$318.00
Regular Shipping:
$9.95
Total:
$327.95
Go To Store

Invega Prices from PrescriptionPoint

Invega 6mg

28
Brand

$318.00

viewdetail

$ 11.36

Go To STORE
23.92%
When you buy 1 container of Invega 6mg for $318.00 at PrescriptionPoint compared to the max price for 28 of $418.00.
PrescriptionPoint Pharmacy is certified by
1 container (28): Invega 6mg
$318.00
Regular Shipping:
$9.95
Total:
$327.95
Go To Store

Invega Prices from Online Canadian Pharmacy

Invega 9mg

28
Brand

$413.83

viewdetail

$ 14.78

Go To STORE
1.00%
When you buy 1 container of Invega 9mg for $413.83 at Online Canadian Pharmacy compared to the max price for 28 of $418.00.
1 container (28): Invega 9mg
$413.83
Regular Shipping:
$0.00
Total:
$413.83
Go To Store

Invega Prices from DoctorSolve

Invega 9mg

28
Brand

$418.00

viewdetail

$ 14.93

Go To STORE
0.00%
When you buy 1 container of Invega 9mg for $418.00 at DoctorSolve compared to the max price for 28 of $418.00.
DoctorSolve Pharmacy is certified by
1 container (28): Invega 9mg
$418.00
Regular Shipping:
$9.95
Coupon Discount
$106.9875
Total:
$320.9625
Go To Store

Invega Prices from MapleLeafMeds

Invega 9mg

28
Brand

$418.00

viewdetail

$ 14.93

Go To STORE
0.00%
When you buy 1 container of Invega 9mg for $418.00 at MapleLeafMeds compared to the max price for 28 of $418.00.
MapleLeafMeds Pharmacy is certified by
1 container (28): Invega 9mg
$418.00
Regular Shipping:
$9.95
Total:
$427.95
Go To Store

Invega Prices from PrescriptionPoint

Invega 9mg

28
Brand

$418.00

viewdetail

$ 14.93

Go To STORE
0.00%
When you buy 1 container of Invega 9mg for $418.00 at PrescriptionPoint compared to the max price for 28 of $418.00.
PrescriptionPoint Pharmacy is certified by
1 container (28): Invega 9mg
$418.00
Regular Shipping:
$9.95
Total:
$427.95
Go To Store

Invega Prices from JanDrugs

Invega Sustenna Injection Kit 50mg

1 syringe
Brand

$495.00

viewdetail

$ 495.00

Go To STORE
66.54%
When you buy 1 container of Invega Sustenna Injection Kit 50mg for $495.00 at JanDrugs compared to the max price for 1 syringe of $1479.50.
JanDrugs Pharmacy is certified by
1 container (1 syringe): Invega Sustenna Injection Kit 50mg
$495.00
Regular Shipping:
$0.00
Coupon Discount
$49.5
Total:
$445.5
Go To Store

Invega Prices from Canada Drugs

Invega Sustenna Injection Kit 78mg/0.5ml

1 syringe
Brand

$495.00

viewdetail

$ 495.00

Go To STORE
66.54%
When you buy 1 container of Invega Sustenna Injection Kit 78mg/0.5ml for $495.00 at Canada Drugs compared to the max price for 1 syringe of $1479.50.
Canada Drugs Pharmacy is certified by
1 container (1 syringe): Invega Sustenna Injection Kit 78mg/0.5ml
$495.00
Regular Shipping:
$0.00
Coupon Discount
$123.75
Total:
$371.25
Go To Store

Invega Prices from CanadianPharmacyKing

Invega 50 mg

1
Brand

$495.00

viewdetail

$ 495.00

Go To STORE
66.54%
When you buy 1 container of Invega 50 mg for $495.00 at CanadianPharmacyKing compared to the max price for 1 of $1479.50.
CanadianPharmacyKing Pharmacy is certified by
1 container (1): Invega 50 mg
$495.00
Regular Shipping:
$10.00
Total:
$505
Go To Store

Invega Prices from JanDrugs

Invega Sustenna Injection Kit 75mg

1 syringe
Brand

$768.90

viewdetail

$ 768.90

Go To STORE
48.03%
When you buy 1 container of Invega Sustenna Injection Kit 75mg for $768.90 at JanDrugs compared to the max price for 1 syringe of $1479.50.
JanDrugs Pharmacy is certified by
1 container (1 syringe): Invega Sustenna Injection Kit 75mg
$768.90
Regular Shipping:
$0.00
Coupon Discount
$76.89
Total:
$692.01
Go To Store

Invega Prices from Canada Drugs

Invega Sustenna Injection Kit 117mg/0.75ml

1 syringe
Brand

$768.90

viewdetail

$ 768.90

Go To STORE
48.03%
When you buy 1 container of Invega Sustenna Injection Kit 117mg/0.75ml for $768.90 at Canada Drugs compared to the max price for 1 syringe of $1479.50.
Canada Drugs Pharmacy is certified by
1 container (1 syringe): Invega Sustenna Injection Kit 117mg/0.75ml
$768.90
Regular Shipping:
$0.00
Coupon Discount
$192.225
Total:
$576.675
Go To Store

Invega Prices from CanadianPharmacyKing

Invega 75 mg

1
Brand

$795.00

viewdetail

$ 795.00

Go To STORE
46.27%
When you buy 1 container of Invega 75 mg for $795.00 at CanadianPharmacyKing compared to the max price for 1 of $1479.50.
CanadianPharmacyKing Pharmacy is certified by
1 container (1): Invega 75 mg
$795.00
Regular Shipping:
$10.00
Total:
$805
Go To Store

Invega Prices from CanadianPharmacyKing

Invega 100 mg

1
Brand

$945.00

viewdetail

$ 945.00

Go To STORE
36.13%
When you buy 1 container of Invega 100 mg for $945.00 at CanadianPharmacyKing compared to the max price for 1 of $1479.50.
CanadianPharmacyKing Pharmacy is certified by
1 container (1): Invega 100 mg
$945.00
Regular Shipping:
$10.00
Total:
$955
Go To Store

Invega Prices from JanDrugs

Invega Sustenna Injection Kit 100mg

1 syringe
Brand

$962.50

viewdetail

$ 962.50

Go To STORE
34.94%
When you buy 1 container of Invega Sustenna Injection Kit 100mg for $962.50 at JanDrugs compared to the max price for 1 syringe of $1479.50.
JanDrugs Pharmacy is certified by
1 container (1 syringe): Invega Sustenna Injection Kit 100mg
$962.50
Regular Shipping:
$0.00
Coupon Discount
$96.25
Total:
$866.25
Go To Store

Invega Prices from Canada Drugs

Invega Sustenna Injection Kit 156mg/1ml

1 syringe
Brand

$962.50

viewdetail

$ 962.50

Go To STORE
34.94%
When you buy 1 container of Invega Sustenna Injection Kit 156mg/1ml for $962.50 at Canada Drugs compared to the max price for 1 syringe of $1479.50.
Canada Drugs Pharmacy is certified by
1 container (1 syringe): Invega Sustenna Injection Kit 156mg/1ml
$962.50
Regular Shipping:
$0.00
Coupon Discount
$240.625
Total:
$721.875
Go To Store

Invega Prices from CanadianPharmacyKing

Invega 150 mg

1
Brand

$1345.00

viewdetail

$ 1,345.00

Go To STORE
9.09%
When you buy 1 container of Invega 150 mg for $1345.00 at CanadianPharmacyKing compared to the max price for 1 of $1479.50.
CanadianPharmacyKing Pharmacy is certified by
1 container (1): Invega 150 mg
$1345.00
Regular Shipping:
$10.00
Total:
$1355
Go To Store

Invega Prices from JanDrugs

Invega Sustenna Injection Kit 150mg

1 syringe
Brand

$1479.50

viewdetail

$ 1,479.50

Go To STORE
0.00%
When you buy 1 container of Invega Sustenna Injection Kit 150mg for $1479.50 at JanDrugs compared to the max price for 1 syringe of $1479.50.
JanDrugs Pharmacy is certified by
1 container (1 syringe): Invega Sustenna Injection Kit 150mg
$1479.50
Regular Shipping:
$0.00
Coupon Discount
$147.95
Total:
$1331.55
Go To Store

Invega Prices from Canada Drugs

Invega Sustenna Injection Kit 234mg/1.5ml

1 syringe
Brand

$1479.50

viewdetail

$ 1,479.50

Go To STORE
0.00%
When you buy 1 container of Invega Sustenna Injection Kit 234mg/1.5ml for $1479.50 at Canada Drugs compared to the max price for 1 syringe of $1479.50.
Canada Drugs Pharmacy is certified by
1 container (1 syringe): Invega Sustenna Injection Kit 234mg/1.5ml
$1479.50
Regular Shipping:
$0.00
Coupon Discount
$369.875
Total:
$1109.625
Go To Store

Invega Information

Product Code
21695-455
Company Name
Rebel Distributors Corp
Dosage From
TABLET, EXTENDED RELEASE
Strength
6 mg
Active Ingredient
paliperidone

Invega ()

Invega () Dosage And Administration

The recommended dose of Invega () (paliperidone) Extended-Release Tablets for the treatment of schizophrenia is 6 mg once daily, administered in the morning. Initial dose titration is not required. Although it has not been systematically established that doses above 6 mg have additional benefit, there was a general trend for greater effects with higher doses. This must be weighed against the dose-related increase in adverse reactions. Thus, some patients may benefit from higher doses, up to 12 mg/day, and for some patients, a lower dose of 3 mg/day may be sufficient. Dose increases above 6 mg/day should be made only after clinical reassessment and generally should occur at intervals of more than 5 days. When dose increases are indicated, increments of 3 mg/day are recommended. The maximum recommended dose is 12 mg/day.

In a longer-term study, Invega () has been shown to be effective in delaying time to relapse in patients with schizophrenia who were stabilized on Invega () for 6 weeks . Invega () should be prescribed at the lowest effective dose for maintaining clinical stability and the physician should periodically reevaluate the long-term usefulness of the drug in individual patients.

The recommended dose of Invega () (paliperidone) Extended-Release Tablets for the treatment of schizoaffective disorder is 6 mg once daily, administered in the morning. Initial dose titration is not required. Some patients may benefit from lower or higher doses within the recommended dose range of 3 to 12 mg once daily. A general trend for greater effects was seen with higher doses. This trend must be weighed against dose-related increase in adverse reactions. Dosage adjustment, if indicated, should occur only after clinical reassessment. Dose increases, if indicated, generally should occur at intervals of more than 4 days. When dose increases are indicated, increments of 3 mg/day are recommended. The maximum recommended dose is 12 mg/day.

Invega () can be taken with or without food. Clinical trials establishing the safety and efficacy of Invega () were carried out in patients without regard to food intake.

Invega () must be swallowed whole with the aid of liquids. Tablets should not be chewed, divided, or crushed. The medication is contained within a nonabsorbable shell designed to release the drug at a controlled rate. The tablet shell, along with insoluble core components, is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet.

Invega () Dosage Forms And Strengths

Invega () Extended-Release Tablets are available in the following strengths and colors: 1.5 mg (orange-brown), 3 mg (white), 6 mg (beige), and 9 mg (pink). All tablets are capsule shaped and are imprinted with either "PAL 1.5", "PAL 3", "PAL 6", or "PAL 9".

Invega () Contraindications

Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. Invega () (paliperidone) is a metabolite of risperidone and is therefore contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in Invega () .

Invega () Warnings And Precautions

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Invega () (paliperidone) is not approved for the treatment of dementia-related psychosis .

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs, including paliperidone. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

If a patient appears to require antipsychotic drug treatment after recovery from NMS, reintroduction of drug therapy should be closely monitored, since recurrences of NMS have been reported.

Paliperidone causes a modest increase in the corrected QT (QTc) interval. The use of paliperidone should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. Paliperidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.

The effects of paliperidone on the QT interval were evaluated in a double-blind, active-controlled (moxifloxacin 400 mg single dose), multicenter QT study in adults with schizophrenia and schizoaffective disorder, and in three placebo- and active-controlled 6-week, fixed-dose efficacy trials in adults with schizophrenia.

In the QT study (n = 141), the 8 mg dose of immediate-release oral paliperidone (n=50) showed a mean placebo-subtracted increase from baseline in QTcLD of 12.3 msec (90% CI: 8.9; 15.6) on day 8 at 1.5 hours post-dose. The mean steady-state peak plasma concentration for this 8 mg dose of paliperidone immediate-release was more than twice the exposure observed with the maximum recommended 12 mg dose of Invega () (C ss = 113 ng/mL and 45 ng/mL, respectively, when administered with a standard breakfast). In this same study, a 4 mg dose of the immediate-release oral formulation of paliperidone, for which C ss = 35 ng/mL, showed an increased placebo-subtracted QTcLD of 6.8 msec (90% CI: 3.6; 10.1) on day 2 at 1.5 hours post-dose. None of the subjects had a change exceeding 60 msec or a QTcLD exceeding 500 msec at any time during this study.

For the three fixed-dose efficacy studies in subjects with schizophrenia, electrocardiogram (ECG) measurements taken at various time points showed only one subject in the Invega () 12 mg group had a change exceeding 60 msec at one time-point on Day 6 (increase of 62 msec). No subject receiving Invega () had a QTcLD exceeding 500 msec at any time in any of these three studies.

A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible appear to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase, but the syndrome can develop after relatively brief treatment periods at low doses, although this is uncommon.

There is no known treatment for established tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself may suppress (or partially suppress) the signs and symptoms of the syndrome and may thus mask the underlying process. The effect of symptomatic suppression on the long-term course of the syndrome is unknown.

Given these considerations, Invega () should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that is known to respond to antipsychotic drugs. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient treated with Invega () , drug discontinuation should be considered. However, some patients may require treatment with Invega () despite the presence of the syndrome.

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with all atypical antipsychotics. These cases were, for the most part, seen in post-marketing clinical use and epidemiologic studies, not in clinical trials, and there have been few reports of hyperglycemia or diabetes in trial subjects treated with Invega () . Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Because Invega () was not marketed at the time these studies were performed, it is not known if Invega () is associated with this increased risk.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Like other drugs that antagonize dopamine D receptors, paliperidone elevates prolactin levels and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.

Hyperprolactinemia, regardless of etiology, may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent , a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. An increase in the incidence of pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary adenocarcinomas, pituitary and pancreatic adenomas) was observed in the risperidone carcinogenicity studies conducted in mice and rats . Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

Because the Invega () tablet is non-deformable and does not appreciably change in shape in the gastrointestinal tract, Invega () should ordinarily not be administered to patients with pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic, for example: esophageal motility disorders, small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudoobstruction, or Meckel's diverticulum). There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of drugs in non-deformable controlled-release formulations. Because of the controlled-release design of the tablet, Invega () should only be used in patients who are able to swallow the tablet whole .

A decrease in transit time, e.g., as seen with diarrhea, would be expected to decrease bioavailability and an increase in transit time, e.g., as seen with gastrointestinal neuropathy, diabetic gastroparesis, or other causes, would be expected to increase bioavailability. These changes in bioavailability are more likely when the changes in transit time occur in the upper GI tract.

Clinical experience with Invega () in patients with certain concomitant illnesses is limited .

Patients with Parkinson's Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.

Invega () has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical trials. Because of the risk of orthostatic hypotension with Invega () , caution should be observed in patients with known cardiovascular disease .

Invega () Adverse Reactions

The following are discussed in more detail in other sections of the labeling:

The most common adverse reactions in clinical trials in subjects with schizophrenia (reported in 5% or more of subjects treated with Invega () and at least twice the placebo rate in any of the dose groups) were extrapyramidal symptoms, tachycardia, and akathisia. The most common adverse reactions in clinical trials in patients with schizoaffective disorder (reported in 5% or more of subjects treated with Invega () and at least twice the placebo rate) were extrapyramidal symptoms, somnolence, dyspepsia, constipation, weight increased, and nasopharyngitis.

The most common adverse reactions that were associated with discontinuation from clinical trials in subjects with schizophrenia (causing discontinuation in 2% of Invega () -treated subjects) were nervous system disorders. The most common adverse reactions that were associated with discontinuation from clinical trials in subjects with schizoaffective disorder were gastrointestinal disorders, which resulted in discontinuation in 1% of Invega () -treated subjects. .

The safety of Invega () was evaluated in 1205 adult subjects with schizophrenia who participated in three placebo-controlled, 6-week, double-blind trials, of whom 850 subjects received Invega () at fixed doses ranging from 3 mg to 12 mg once daily. The information presented in this section was derived from pooled data from these three trials. Additional safety information from the placebo-controlled phase of the long-term maintenance study, in which subjects received Invega () at daily doses within the range of 3 mg to 15 mg (n=104), is also included.

The safety of Invega () was also evaluated in 622 adult subjects with schizoaffective disorder who participated in two placebo-controlled, 6-week, double-blind trials. In one of these trials, 206 subjects were assigned to one of two dose levels of Invega () : 6 mg with the option to reduce to 3 mg (n = 108) or 12 mg with the option to reduce to 9 mg (n = 98) once daily. In the other study, 214 subjects received flexible doses of Invega () (3–12 mg once daily). Both studies included subjects who received Invega () either as monotherapy or as an adjunct to mood stabilizers and/or antidepressants. Adverse events during exposure to study treatment were obtained by general inquiry and recorded by clinical investigators using their own terminology. Consequently, to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.

Throughout this section, adverse reactions are reported. Adverse reactions are adverse events that were considered to be reasonably associated with the use of Invega () (adverse drug reactions) based on the comprehensive assessment of the available adverse event information. A causal association for Invega () often cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Invega () Drug Interactions

Given the primary CNS effects of paliperidone , Invega () should be used with caution in combination with other centrally acting drugs and alcohol. Paliperidone may antagonize the effect of levodopa and other dopamine agonists.

Because of its potential for inducing orthostatic hypotension, an additive effect may be observed when Invega () is administered with other therapeutic agents that have this potential .

Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.

Paliperidone is a weak inhibitor of P-glycoprotein (P-gp) at high concentrations. No data are available and the clinical relevance is unknown.

Pharmacokinetic interaction between lithium and Invega () is unlikely.

In a clinical study, subjects on a stable dose of valproate showed comparable valproate average plasma concentrations when 3–15 mg of Invega () was added to their existing valproate treatment.

Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. studies have shown that paliperidone is a P-gp substrate.

Co-administration of Invega () 6 mg once daily with carbamazepine 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state C and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. On initiation of carbamazepine, the dose of Invega () should be re-evaluated and increased if necessary. Conversely, on discontinuation of carbamazepine, the dose of Invega () should be re-evaluated and decreased if necessary.

Paliperidone is metabolized to a limited extent by CYP2D6 . In an interaction study in healthy subjects in which a single 3 mg dose of Invega () was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4, 30) higher in CYP2D6 extensive metabolizers. Higher doses of paroxetine have not been studied. The clinical relevance is unknown.

Co-administration of a single dose of Invega () 12 mg with divalproex sodium extended-release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the C and AUC of paliperidone. Dosage reduction for Invega () should be considered when Invega () is co-administered with valproate after clinical assessment.

Pharmacokinetic interaction between lithium and Invega () is unlikely.

Invega () Use In Specific Populations

The safety, tolerability, and efficacy of Invega () were evaluated in a 6-week placebo-controlled study of 114 elderly subjects with schizophrenia (65 years of age and older, of whom 21 were 75 years of age and older). In this study, subjects received flexible doses of Invega () (3 mg to 12 mg once daily). In addition, a small number of subjects 65 years of age and older were included in the 6-week placebo-controlled studies in which adult schizophrenic subjects received fixed doses of Invega () (3 mg to 15 mg once daily) . There were no subjects ≥ 65 years of age in the schizoaffective disorder studies.

Overall, of the total number of subjects in schizophrenia clinical studies of Invega () (n = 1796), including those who received Invega () or placebo, 125 (7.0%) were 65 years of age and older and 22 (1.2%) were 75 years of age and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney and clearance is decreased in patients with moderate to severe renal impairment , who should be given reduced doses. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function .

Invega () Overdosage

While experience with paliperidone overdose is limited, among the few cases of overdose reported in pre-marketing trials, the highest estimated ingestion of Invega () was 405 mg. Observed signs and symptoms included extrapyramidal symptoms and gait unsteadiness. Other potential signs and symptoms include those resulting from an exaggeration of paliperidone's known pharmacological effects, i.e., drowsiness and somnolence, tachycardia and hypotension, and QT prolongation. Torsade de pointes and ventricular fibrillation have been reported in a patient in the setting of overdose.

Paliperidone is the major active metabolite of risperidone. Overdose experience reported with risperidone can be found in the OVERDOSAGE section of the risperidone package insert.

There is no specific antidote to paliperidone, therefore, appropriate supportive measures should be instituted and close medical supervision and monitoring should continue until the patient recovers. Consideration should be given to the extended-release nature of the product when assessing treatment needs and recovery. Multiple drug involvement should also be considered.

In case of acute overdose, establish and maintain an airway and ensure adequate oxygenation and ventilation. Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered.

The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.

Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of paliperidone. Similarly the alpha-blocking properties of bretylium might be additive to those of paliperidone, resulting in problematic hypotension.

Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of paliperidone-induced alpha blockade). In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered.

Invega () Description

Paliperidone, the active ingredient in Invega () Extended-Release Tablets, is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. Invega () contains a racemic mixture of (+)- and (-)- paliperidone. The chemical name is (±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one. Its molecular formula is CHFNO and its molecular weight is 426.49. The structural formula is:

Paliperidone is sparingly soluble in 0.1N HCl and methylene chloride; practically insoluble in water, 0.1N NaOH, and hexane; and slightly soluble in N,N-dimethylformamide.

Invega () (paliperidone) Extended-Release Tablets are available in 1.5 mg (orange-brown), 3 mg (white), 6 mg (beige), and 9 mg (pink) strengths. Invega () utilizes OROS osmotic drug-release technology .

Inactive ingredients are carnauba wax, cellulose acetate, hydroxyethyl cellulose, propylene glycol, polyethylene glycol, polyethylene oxides, povidone, sodium chloride, stearic acid, butylated hydroxytoluene, hypromellose, titanium dioxide, and iron oxides. The 3 mg tablets also contain lactose monohydrate and triacetin.

Invega () Clinical Pharmacology

Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C) approximately 24 hours after dosing. The pharmacokinetics of paliperidone following Invega () administration are dose-proportional within the available dose range. The terminal elimination half-life of paliperidone is approximately 23 hours.

Steady-state concentrations of paliperidone are attained within 4–5 days of dosing with Invega () in most subjects. The mean steady-state peak:trough ratio for an Invega () dose of 9 mg was 1.7 with a range of 1.2–3.1.

Following administration of Invega () , the (+) and (-) enantiomers of paliperidone interconvert, reaching an AUC (+) to (-) ratio of approximately 1.6 at steady state.

Invega () Clinical Studies

The acute efficacy of Invega () (3 mg to 15 mg once daily) was established in three placebo-controlled and active-controlled (olanzapine), 6-week, fixed-dose trials in non-elderly adult subjects (mean age of 37) who met DSM-IV criteria for schizophrenia. Studies were carried out in North America, Eastern Europe, Western Europe, and Asia. The doses studied among these three trials included 3 mg/day, 6 mg/day, 9 mg/day, 12 mg/day, and 15 mg/day. Dosing was in the morning without regard to meals.

Efficacy was evaluated using the Positive and Negative Syndrome Scale (PANSS), a validated multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression. Efficacy was also evaluated using the Personal and Social Performance (PSP) scale. The PSP is a validated clinician-rated scale that measures personal and social functioning in the domains of socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors.

In all 3 studies (n = 1665), Invega () was superior to placebo on the PANSS at all doses. Mean effects at all doses were fairly similar, although the higher doses in all studies were numerically superior. Invega () was also superior to placebo on the PSP in these trials.

An examination of population subgroups did not reveal any evidence of differential responsiveness on the basis of gender, age (there were few patients over 65), or geographic region. There were insufficient data to explore differential effects based on race.

In a longer-term trial, adult outpatients meeting DSM-IV criteria for schizophrenia who had clinically responded (defined as PANSS score ≤ 70 or ≤ 4 on pre-defined PANSS subscales, as well as having been on a stable fixed dose of Invega () for the last two weeks of an 8-week run-in phase) were entered into a 6-week open-label stabilization phase where they received Invega () (doses ranging from 3 mg to 15 mg once daily). After the stabilization phase, patients were randomized in a double-blind manner to either continue on Invega () at their achieved stable dose, or to placebo, until they experienced a relapse of schizophrenia symptoms. Relapse was pre-defined as significant increase in PANSS (or pre-defined PANSS subscales), hospitalization, clinically significant suicidal or homicidal ideation, or deliberate injury to self or others. An interim analysis of the data showed a significantly longer time to relapse in patients treated with Invega () compared to placebo, and the trial was stopped early because maintenance of efficacy was demonstrated.

The acute efficacy of Invega () (3 mg to 12 mg once daily) in the treatment of schizoaffective disorder was established in two placebo-controlled, 6‑week trials in non-elderly adult subjects. Enrolled subjects 1) met DSM-IV criteria for schizoaffective disorder, as confirmed by the Structured Clinical Interview for DSM-IV Disorders, 2) had a Positive and Negative Syndrome Scale (PANSS) total score of at least 60, and 3) had prominent mood symptoms as confirmed by a score of at least 16 on the Young Mania Rating Scale and/or Hamilton Rating Scale for Depression. The population included subjects with schizoaffective bipolar and depressive types. In one of these trials, efficacy was assessed in 211 subjects who received flexible doses of Invega () (3-12 mg once daily). In the other study, efficacy was assessed in 203 subjects who were assigned to one of two dose levels of Invega () : 6 mg with the option to reduce to 3 mg (n = 105) or 12 mg with the option to reduce to 9 mg (n = 98) once daily. Both studies included subjects who received Invega () either as monotherapy [no mood stabilizers and/or antidepressants (55%)] or as an adjunct to mood stabilizers and/or antidepressants (45%). The most commonly used mood stabilizers were valproate and lithium. The most commonly used antidepressants were SSRIs and SNRIs. Invega () was dosed in the morning without regard to meals. Studies were carried out in the United States, Eastern Europe, Russia, and Asia.

Efficacy was evaluated using the PANSS, a validated multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression. As secondary outcomes, mood symptoms were evaluated using the Hamilton Depression Rating Scale (HAM-D-21) and the Young Mania Rating Scale (YMRS).

The Invega () group in the flexible-dose study (dosed between 3 and 12 mg/day, mean modal dose of 8.6 mg/day) and the higher dose group of Invega () in the 2 dose-level study (12 mg/day with option to reduce to 9 mg/day) were each superior to placebo in the PANSS. Numerical improvements in mood symptoms were also observed, as measured by the HAM-D-21 and YMRS. In the lower dose group of the 2 dose-level study (6 mg/day with option to reduce to 3 mg/day), Invega () was not significantly different from placebo as measured by the PANSS.

Taking the results of both studies together, Invega () improved the symptoms of schizoaffective disorder at endpoint relative to placebo when administered either as monotherapy or as an adjunct to mood stabilizers and/or antidepressants. An examination of population subgroups did not reveal any evidence of differential responsiveness on the basis of gender, age, or geographic region. There were insufficient data to explore differential effects based on race.

Invega () How Supplied/storage And Handling

Invega () (paliperidone) Extended-Release Tablets are available in the following strengths and packages. All tablets are capsule-shaped.

6 mg tablets are beige and imprinted with "PAL 6", and are available in bottles of 30 (NDC 21695-455-30).

Invega () Patient Counseling Information

Physicians are advised to discuss the following issues with patients for whom they prescribe Invega () .

Invega ()

Invega () Principal Display Panel

Featured In
footer logo
©2015,eDrugSearch,Inc. All Rights Reserved. Privacy Policy Terms of Use Contact UsSitemap
Sign In

Email Address
Password
 
Remember Me Forgot your password?
Create Account
Forgot Password

If you've forgotten your password, please enter your email address below. We'll send you an email with instructions for resetting your password.

Email Address
Create Account

Name
Email ID
Password
Human Verification
Please type the characters you see in the image.
 
I have read and agree to the terms of service
Sign In
Submit Your Blog

Sorry ! only healthcare users can submit blogs. Please Click here to login or sign up for Healthcare User.